focus -WSS

focus

author：Wikipedia 2025-09-28 18:30:40 - browse：18345

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： For one rare type of lung cancer, Pfizer pill reduces progression by 81%

explore

WSS

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Oprah kicked off a national conversation on obesity. Let's have it

Primary care physicians play key roles in Alzheimer's management

Let's speed up science by embracing open access publishing

Food as medicine: Medically tailored meals may get standardized

With trial win, GSK could get blood cancer drug back on market

leisure time

focus

knowledge

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Trump demands the U.S. pay no more for drugs than other countries … again

Intellia reports positive results for its CRISPR

At least 13 dead in Texas as scorching temps continue

Merck drug for rare lung condition set for approval in U.S.

Guidelines to prevent youth baseball injuries need more muscle

HIV drugs protect against transmission, even in unprotected sex

After affirmative action ruling, medical educators look to 'holistic review'

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

leisure time

The Readout: Lenmeldy, GLP

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

See how much Covid

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Decaf coffee targeted by food safety group under obscure FDA rule

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

focus

focus

explore

focus